The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
The new capital is expected to fund the company through 2029
The center combines rigorous scientific instruction with practical, hands-on training, equipping providers with the clinical, consultative, and business skills needed to deliver safe, effective, and patient-centered care
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
Opioid dependence remains a major driver of death and disease worldwide
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
